Fungal infections and antifungal resistance are increasingly recognized. Antifungal susceptibility testing remains unstandardized, and a particularly important problem is endpoint determination. In this paper we propose the yeast metabolic reduction of the tetrazolium salt 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyll-2H-tetrazolium hydroxide (XTT) as a colorimetric endpoint which is quantitative and objective. Amphotericin B, fluorocytosine, and fluconazole dose-response curves were obtained, and a metabolic MIC could be determined by using precise criteria.
Yeast infections are an increasingly important problem, particularly in immunocompromised patients. The recognition of antifungal resistance stresses the need for improved susceptibility testing. Unfortunately, antifungal drug susceptibility assays have been difficult to standardize (6, 11, 15, 16, 18) . While considerable progress has been made, the determination of endpoints is still not satisfactory. In most assays endpoints are determined by visually grading turbidity, a subjective operation, particularly problematic when testing azole drugs for which trailing endpoints are common (4, 7, 9) . In this paper we describe an innovative colorimetric, quantitative method of endpoint determination for susceptibility testing based on the reduction of a tetrazolium salt.
Tetrazolium salts are widely used as indicators of reducing systems (2, 10) . When reduced they give rise to a colored formazan crystal. Because these agents are cleaved by various dehydrogenase enzymes, active mitochondria will produce colored formazans and provide a colorimetric method to detect metabolically active cells. By using a spectrophotometer or an enzyme-linked immunosorbent assay (ELISA) plate reader, this methodology is amenable to quantitation. One tetrazolium salt, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (MTT), has been used for anticancer drug assays (1, 13, 20) .
Historically, formazans were water insoluble and could not easily be quantified without performing additional steps involving centrifugation of cells and removal of media, use of an organic solvent such as dimethyl sulfoxide, and occasionally sonication. Recently a new tetrazolium salt, 2,3-bis (2- 
methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino)carbonyl]-
2H-tetrazolium hydroxide (XTT), which after reduction yields a water-soluble formazan, has been synthesized (14) . XTT-based assays have also been used in a variety of eukaryotic cell drug assays (3, 17, 21) . We describe a drug susceptibility assay for yeasts based on XTT reduction and quantitation of the resulting colored formazan solution.
MATERIALS AND ditional strains of Candida lusitaniae (including C. lusitaniae FR-8900) were obtained from R. Summerbell (Provincial Health Laboratory, Toronto, Canada). Organisms were maintained on Sabouraud agar plates at room temperature and were passaged once a month. All tests were performed using an overnight broth culture of the organism.
Broth. Buffered yeast nitrogen base (BYNB) was modified according to the method of Shadomy et al. with glucose (1%) and asparagine (0.15%) (18) . A lOx solution was prepared in water and diluted with phosphate buffer, and the broth was then sterilized by filtration.
XTT. XTT was obtained from Sigma or Polysciences
(catalog no. X4521 or catalog 19661). Because of the poor solubility of XTT in BYNB, the XTT stock was prepared as a saturated solution in Ringer's lactate by mixing 1 mg of XTT per ml in Ringer's lactate, resulting in almost complete dissolution of XTT. The solution was filtered through a 0.22 ,um-pore-size filter, aliquoted, and stored at -70°C until needed.
PMS. Phenazine methyl sulfate (PMS) (Sigma catalog no. P9625) was prepared as a stock solution of 5 mM (1.53 mg/ml) in BYNB, filter sterilized, and kept at 4°C until needed.
MEN. Menadione (MEN) (Sigma catalog no. M5625) as a stock solution of 10 mM (1.72 mg/ml) was prepared in acetone, aliquoted, and stored at -70°C until needed.
Amphotericin B. Amphotericin B was the parenteral preparation from Squibb; 50 mg was resuspended in sterile water, and the resulting solution was diluted in BYNB to a stock solution of 0.5 mg/ml. The solution was aliquoted and stored at -70°C until needed. Unused aliquots were discarded after 1 month (12).
5-FC. XTT reduction curves. In order to determine the relationship between the amount of XTT reduction and the amount of live yeast, XTT reduction curves were determined for several species. Yeasts were grown overnight in BYNB at 35°C to obtain a concentrated suspension of yeast. This suspension was serially diluted in a 1:1 ratio with BYNB in a series of eight disposable culture tubes (12 by 75 mm) (the final volume in each tube was 1 ml). The most concentrated suspension used was a 1:1 dilution of the overnight growth. A CFU count was performed by diluting the remaining 1 ml 10-fold in BYNB, vortexing it, and plating 10 RI on a Sabouraud agar plate. XTT reduction assays were performed with each tube as described above.
Antifungal susceptibility assay. The antifungal agent to be tested was thawed, diluted 10-fold in 1 ml of BYNB, and serially diluted in disposable culture tubes (12 by 75 mm). Drug-free control tubes were included in all series. Final concentrations ranged from 25 to 0.003 mg/liter for amphotericin B and 100 to 0.012 mg/liter for fluconazole and 5-FC. The inoculum was prepared from an overnight growth at 35°C of the organism in BYNB; this suspension was diluted in BYNB to obtain a 95% transmission at 530 nm (15) (approximately 2 x 106 CFU/ml). Fifty microliters of the suspension was added to each tube, 10 RI was added to 1 ml of BYNB, and 10 RI of this dilution was plated on Sabouraud agar for a CFU count. Tubes were incubated at 30°C with shaking for 24 h. Thereafter an XTT assay was performed. Drug susceptibility assays were performed in triplicate. For each drug concentration and for the control tubes (no drug), the mean and standard deviation were computed. Results are shown as relative optical density (OD) (i.e., mean OD of each concentration divided by the mean OD of the drug-free tubes). Error bars were computed as follows. For each drug concentration the absolute error was taken as 1 standard deviation. The relative error on the relative OD was therefore the sum of the relative errors; the absolute error on the relative OD was computed from the relative error.
XT reduction curves of C. albicans TTH-156 in the presence of antifungal agents. A standard inoculum of C albicans 156 was prepared as described above. Fifty microliters was inoculated into tubes containing antifungal agents at specified concentrations and into drug-free control broth. Tubes were incubated with shaking at 30°C for 24 h and serially diluted in a 1:1 ratio with media containing the same concentration of antifungal agent as the initial tubes. The last 1 ml was used to perform a CFU count. An XTT assay was performed as described above. If the linear log-log relationship in Fig. 1 holds in the presence of amphotericin B, this means that at any amphotericin B concentration x we have the following: log OD(x) = k log CFU(x), where k is a constant. Hence, at all x, log OD(x)/log OD(0) = log CFU(x)/log CFU(0), where x = 0 represents the drug-free control tubes. (8) . Figure 4 illustrates the dose-response curves of the strains tested with fluconazole. Two (2) and has been exploited to develop anticancer drug assays based on the tetrazolium salt MTT (1, 13, 20) .
RESULTS

XTT
The intensity of the reaction depends on several characteristics of the culture studied, including the number of live cells, the amounts of cellular proteins, and cellular metabolic activity (activated cells metabolize MTT more readily [13] ). Drugs which affect cell turnover and metabolic activity will affect tetrazolium reduction. The duction is a measure of cellular metabolic activity, and it does not require cellular division, in contrast to 3H incorporation assays. In practice there is good agreement between results of MIT assays and 3H incorporation assays (5, 13) . MTT assays, because of the insolubility of the resulting formazan, necessitated extra steps, such as centrifugation, aspiration of the media, use of an organic solvent such as dimethyl sulfoxide, and sometimes sonication, to quantitate the amount of formazan generated. The X1T tetrazolium salt differs in that it produces a water-soluble formazan (14) . XTT-based assays have been used for antiviral (21) , anticancer (17) , and antifilarial (3) (2) . By reducing the concentration of MEN, these problems disappear and we obtain a family of well-behaved curves for all species tested under the same conditions. We have not (19) .
The dose-response curve obtained for amphotericin B essentially drops to baseline once the MIC is exceeded. This corresponds with the visual inspection of the tubes which show no growth at high concentrations of amphotericin B. This is in agreement with previous observations (4). For amphotericin B the corresponding decrease in CFU mirrors the decrease in the relative OD. As demonstrated in Fig. 2b , the linear log-log relationship appears to be preserved, suggesting that for the amphotericin B susceptibility assay, XTT reduction is a good indicator of the CFU count.
Although the XTT assay was applicable to many yeast species (Fig. 4) , because of its weaker absolute signal (Fig. 1) T. glabrata had to be incubated for 48 h to be analyzed. For T. glabrata small absolute variations in OD therefore resulted in greater changes in the relative OD. More experience with slowly growing yeasts will be required before this assay can be relied upon. Dose-response curves for fluconazole (Fig. 4) illustrate the phenomenon of trailing endpoints or "ghosting" (7, 9, 11) . In general, the yeast isolates we tested exhibited a gradual rather than an abrupt decrease in XTT reduction in relation to fluconazole. These two features underline the potential benefits of a colorimetric assay which can be used to obtain a defined endpoint or MIC. It is interesting to speculate that the in vitro trailing phenomenon and shape of the susceptibility curves may have some relevance to the clinical efficacy of the drug.
A proposed definition of an antifungal MIC has been "the lowest concentration of drug that produces the greatest reduction in growth as compared to the control" (11) . This entails a degree of subjectivity if the endpoint is determined As pointed out by Espinel-Ingroff et al. (4) , standardization of a microdilution assay would be desirable. This methodology has been used in the field of cancer research, where quantitation is provided by using an ELISA plate reader (13, 17) . ELISA methodology could be used to determine yeast MICs by microdilution.
RPMI has recently been suggested as a suitable medium for antifungal susceptibility testing (4, 11, 16) . XT1-based susceptibility assays for antifilarial drugs have used RPMI successfully as the testing broth (3). It is also possible that modifications in the assay could improve the range of fungi that can be assessed by this technique. The ability to provide an objective endpoint for susceptibility testing would, it is hoped, contribute to the establishment of standardized antifungal drug assays.
